Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos

Archives of Toxicology

Volumn 85, Issue 3, 2011, Pages 185-192

  Gube, M ^a,d   Taeger, D ^b   Weber, D G ^b   Pesch, B ^b   Brand, P ^a   Johnen, G ^b   Muller Lux A ^a   Gross, I M ^b   Wiethege, T ^b   Weber, A ^b   Raithel, H J ^c   Kraus, T ^a   Bruning T ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Asbestos exposure; Lung cancer; Mesothelioma; SMRP; Tumor marker

Indexed keywords

ASBESTOS; CA 125 ANTIGEN; CYTOKERATIN 19 FRAGMENT; PEPTIDE DERIVATIVE; SOLUBLE MESOTHELIN RELATED PEPTIDE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INDUSTRIAL WORKER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; OCCUPATIONAL CANCER; OCCUPATIONAL EXPOSURE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 79954425564     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00204-010-0580-2     Document Type: Article

References (39)

1. A Agudo CA Gonzalez MJ Bleda 2000 Occupation and risk of malignant pleural mesothelioma: a case control study in Spain Am J Ind Med 37 159 168 1:STN:280:DC%2BD3c%2Fot1Ohsg%3D%3D 10.1002/(SICI)1097-0274(200002)37:2<159:: AID-AJIM1>3.0.CO;2-0 10615096 (Pubitemid 30036726)
2. C Andreadis S Touloupidis G Galaktidou AH Kortsaris A Boutis D Mouratidou 2005 Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy J Urol 174 1771 1775 1:CAS:528:DC%2BD2MXhtV2rt7vJ 10.1097/01.ju.0000176742.53556.25 16217281 (Pubitemid 41546932)
3. Arendt M, Bauer HD, Blome H et al. (2007) BK-Report 1/2007-Faserjahre. Berufsgenossenschaftliche Hinweise zur Ermittlung der kumulativen Asbestfaserstaub-Dosis am Arbeitsplatz (Faserjahre) und Bearbeitungshinweise zur Berufskrankheit Nr. 4104.,Lungenkrebs oder Kehlkopfkrebs". Deutsche gesetzliche Unfallversicherung (DGUV), ed. St. Augustin, Germany
4. HL Beyer RD Geschwindt CL Glover L Tran I Hellstrom KE Hellstrom MC Miller T Verch WJ Allward HI Pass NY Sardesai 2007 Mesomark™: a potential test for malignant pleural mesothelioma Clin Chem 53 666 672 1:CAS:528:DC%2BD2sXksFChur4%3D 10.1373/clinchem.2006.079327 17289801 (Pubitemid 46580236)
5. C Bianchi L Giarelli G Grnadi A Brollo L Ramani C Zuch 1997 Latency periods in asbestos-related mesotheliom of the pleura Eur J Cancer Prev 6 162 166 1:STN:280:DyaK2szotVaktA%3D%3D 9237066 (Pubitemid 27296781)
6. DE Brenner DP Normolle 2007 Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum Editorial Cancer Epidemiol Biomarkers Prev 16 1918 1920 1:CAS:528:DC%2BD2sXhtFGjtLfJ 10.1158/1055-9965.EPI-07-2619 (Pubitemid 47621163)
7. K Chang I Pastan 1996 Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers Proc Natl Acad Sci USA 93 136 140 1:CAS:528:DyaK28XjslyjtA%3D%3D 10.1073/pnas.93.1.136 8552591 (Pubitemid 26041483)
8. CJ Clopper ES Pearson 1934 The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 26 404 413 10.1093/biomet/26.4.404
9. J Creaney BW Robinson 2009 Serum and pleural fluid biomarkers for mesothelioma Curr Opin Pulm Med 15 366 370 1:CAS:528:DC%2BD1MXmslyitLg%3D 10.1097/MCP.0b013e32832b98eb 19417672
10. A Cristaudo R Foddis A Vivaldi G Guglielmi N Dipalma R Filiberti M Neri M Ceppi M Paganuzzi GP Ivaldi M Mencoboni PA Canessa N Ambrosino A Chella L Mutti R Puntoni 2007 Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer Clin Cancer Res 13 5076 5081 1:CAS:528: DC%2BD2sXpvFGru7c%3D 10.1158/1078-0432.CCR-07-0629 17785560 (Pubitemid 47502073)
11. ER DeLong DM DeLong DL Clarke-Pearson 1988 Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 837 845 1:STN:280:DyaL1M%2Fns12ksQ%3D%3D 10.2307/2531595 3203132
12. RM Gaafar NH Eldin 2005 Epidemic of mesothelioma in Egypt Lung Cancer 49 Suppl1 17 20 10.1016/j.lungcan.2005.03.025 (Pubitemid 40798838)
13. AM Gattani J Mandeli HW Bruckner 1996 Tumor markers in patients with pancreatic carcinoma Cancer 78 57 62 1:STN:280:DyaK283ms12htw%3D%3D 10.1002/(SICI)1097-0142(19960701)78:1<57::AID-CNCR10>3.0.CO;2-6 8646727 (Pubitemid 26189905)
14. O Hagemeyer H Otten T Kraus 2006 Asbestos consumption, asbestos exposure and asbestos-related occupational diseases in Germany Int Arch Occup Environ Health 79 613 620 1:CAS:528:DC%2BD28XotFCht7s%3D 10.1007/s00420-006-0091-x 16523318 (Pubitemid 44227702)
15. KD Hatzakis ME Froudarakis D Bouros N Tzanakis N Karkavitsas NM Siafakas 2002 Prognostic value of serum tumor markers in patients with lung cancer Respiration 69 25 29 1:CAS:528:DC%2BD38XhtFOqsrc%3D 10.1159/000049366 11844959 (Pubitemid 34158384)
16. I Hellstrom J Raycraft S Kanan NY Sardesai T Verch Y Yang KE Hellstrom 2006 Mesothelin variant 1 is released from tumor cells as a diagnostic marker Cancer Epidemiol Biomarkers Prev 15 1014 1020 1:CAS:528:DC%2BD28XksFeitb8%3D 10.1158/1055-9965.EPI-05-0334 16702385 (Pubitemid 43823532)
17. M Ho M Onda QC Wang R Hassan I Pastan MO Lively 2006 Mesothelin is shed from tumor cells Cancer Epidemiol Biomarkers Prev 15 1751 10.1158/1055-9965.EPI- 06-0479 16985043 (Pubitemid 44497117)
18. JT Hodgson DM McElvenny AJ Darnton MJ Price J Peto 2005 The extend burden of mesothelioma mortality in Great Britain from 2002 to 2050 Br J Cancer 92 587 593 1:STN:280:DC%2BD2M%2Fnt1Whsw%3D%3D 15668716 (Pubitemid 40395543)
19. D Howel A Gibbs 1999 Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region Occup Environ Med 56 51 58 1:STN:280:DyaK1M3ntlaqsQ%3D%3D 10.1136/oem.56.1.51 10341747 (Pubitemid 29103649)
20. Kraus T, Raithel HJ (1998) Frühdiagnostik asbeststaubverursachter Erkrankungen. Deutsche gesetzliche Unfallversicherung (DGUV), ed. St. Augustin, Germany
21. Q-L Liang H-Z Shi X-J Qin X-D Liang J Jiang H-B Yang 2008 Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis Thorax 63 35 41 10.1136/thx.2007.077958 17573438
22. D Martino HI Pass 2004 Integration of multimodality approaches in the management of malignant pleural mesothelioma Clin Lung Cancer 5 290 298 10.3816/CLC.2004.n.008 15086967 (Pubitemid 38618239)
23. MW McIntosh C Drescher B Karlan N Scholler N Urban KE Hellstrom, et al. 2004 Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma Gynecol Oncol 95 9 15 1:CAS:528:DC%2BD2cXnvVOisrk%3D 10.1016/j.ygyno.2004.07.039 15385104 (Pubitemid 39286271)
24. V Neumann A Rutten M Scharmach, et al. 2004 Factors influencing long-term survival in mesothelioma patients-results of the German mesothelioma register Int Arch Occup Environ Health 77 191 199 1:STN:280:DC%2BD2c7kvVKlug%3D%3D 10.1007/s00420-003-0498-6 14991330 (Pubitemid 38678976)
25. M Paganuzzi M Onetto P Marroni R Filiberti E Tassara S Parodi, et al. 2001 Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma Chest 119 1138 1142 1:STN:280:DC%2BD3M3jslKrsA%3D%3D 10.1378/chest.119.4.1138 11296181 (Pubitemid 32679442)
26. S Pandita 2006 Banning asbestos in Asia: campaigns and strategies by the Asian Network for the rights of Occupational Accident Victims (ANROAV) Int J Occup Environ Health 12 248 253 1:CAS:528:DC%2BD28XpvFeit7s%3D 16967832 (Pubitemid 44289957)
27. EK Park A Sandrini DH Yates PS Thomas J Creaney BW Robinson AR Johnson 2008 Soluble Mesothelin Related Protein (SMRP) in an asbestos exposed population: the Dust Diseases Board cohort study Am J Respir Crit Care Med 178 827 832
28. B Pesch D Taeger G Johnen IM Gross DG Weber M Gube A Müller-Lux E Heinze T Wiethege V Neumann A Tannapfel HJ Raithel T Brüning T Kraus 2010 Cancer mortality in a surveillance cohort of German males formerly exposed to asbestos Int J Hyg Environ Health 213 44 51 10.1016/j.ijheh.2009.09.001 19783208
29. J Peto A Decarli C La Vecchia F Levi E Negri 1999 The European mesothelioma epidemic Br J Cancer 79 666 672 1:STN:280:DyaK1M7kvFGqsQ%3D%3D 10.1038/sj.bjc.6690105 10027347 (Pubitemid 29046253)
30. BW Robinson RA Lake 2005 Advances in malignant mesothelioma N Engl J Med 353 1591 1603 1:CAS:528:DC%2BD2MXhtFWhur7O 10.1056/NEJMra050152 16221782 (Pubitemid 41434638)
31. BW Robinson J Creaney R Lake A Nowak AW Musk N de Klerk P Winzel KE Hellstrom I Hellstrom 2003 Mesothelin-family proteins and diagnosis of mesothelioma Lancet 362 1612 1616 1:CAS:528:DC%2BD3sXovF2rsrk%3D 10.1016/S0140-6736(03)14794-0 14630441 (Pubitemid 37443528)
32. JA Rodríguez Portal E Rodríguez Becerra D Rodríguez Rodríguez I Alfageme Michavila A Quero Martínez C Diego Roza A León Jiménez I Isidro Montes P Cebollero Rivas 2009 Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure Cancer Epidemiol Biomarkers Prev 18 646 650 10.1158/1055-9965.EPI-08-0422 19190155
33. OD Roe J Creaney S Lundgren E Larsson H Sandeck P Boffetta TI Nilsen B Robinson K Kjaerheim 2008 Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study Lung Cancer 61 235 243 10.1016/j.lungcan.2007.12.025 18281122
34. CW Ryan J Herndon NJ Vogelzang 1998 A review of chemotherapy trials for malignant mesothelioma Chest 113 Suppl 66 73 10.1378/chest.113.1-Supplement.66S
35. K Takahashi A Karjalainen 2003 A cross-country comparative overview of the asbestos situation in ten Asian countries Int J Occup Environ Health 9 244 248 12967160 (Pubitemid 40292092)
36. NJ Vogelzang JJ Rusthoven J Symanowski, et al. 2003 Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2636 2644 1:CAS:528: DC%2BD2cXptlCktL4%3D 10.1200/JCO.2003.11.136 12860938 (Pubitemid 46606305)
37. DG Weber D Taeger B Pesch T Kraus T Bruening G Johnen 2007 Soluble mesothelin-related petides (SMRP)-high stability of a potential tumor marker for mesothelioma Cancer Biomark 3 287 292 1:CAS:528:DC%2BD1cXhtVOrt7Y%3D 18048966 (Pubitemid 350187031)
38. DG Weber G Johnen D Taeger A Weber IM Gross B Pesch T Kraus T Brüning M Gube 2010 Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum Biomark Insights 5 1 8 1:CAS:528:DC%2BC3cXhs1Cjt7k%3D 10.4137/BMI.S3927 20130785
39. L Zellos DC Christiani 2004 Epidemiology, biologic behaviour, and natural history of mesothelioma Thorac Surg Clin 14 479 487 10.1016/j.thorsurg.2004.06. 011 (Pubitemid 39314480)